Fully searchable access to the August 1, 2009 issue
Stealth BioTherapeutics announces data from Phase 2 study of geographic atrophy candidate
Ocuphire announces positive topline results from LYNX-1 Phase 3 trial
Kala reaches deal to sell Eysuvis, Inveltys to Alcon
